Second collaboration agreement confirmed between MAB Discovery and BioNTech

MAB Discovery has entered into a second collaboration agreement with European biopharmaceutical company, BioNTech, which will see MAB Discovery’s technology platform applied to proprietary targets provided by BioNTech.

“We are excited to be selected again as a partner for BioNTech. This underscores the high performance of our rabbit-based antibody discovery platform,” said Dr Stephan Fischer, CEO of MAB Discovery.

Sean Marett, COO of BioNTech added: “Our collaboration with MAB Discovery in 2013 was highly productive and we are delighted to expand our relationship to generate unique antibodies against a set of therapeutically relevant targets.”

Financial terms of the agreement were not disclosed.